Chieh-Sheng Lu Jin-Hwang Liu
10.1097/MD.0000000000005747
Medicine (Baltimore)
2017 Jan;96(1):e5747.
CC BY-SA
https://pubmed.ncbi.nlm.nih.gov/28072716/
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents / adverse effects Neoplasms / therapy Pneumonia / etiology
Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents / adverse effects Neoplasms / therapy Pneumonia / etiology Case Reports Adenocarcinoma / secondary Adenocarcinoma / therapy Aged Chemoradiotherapy Humans Jejunal Neoplasms / pathology Lung Neoplasms / secondary Lung Neoplasms / therapy Male Melanoma, Amelanotic / secondary Melanoma, Amelanotic / therapy Middle Aged Neoplasms / pathology Nivolumab Pneumonia / chemically induced Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / pathology Thymoma / secondary Thymoma / therapy Thymus Neoplasms / pathology Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab pembrolizumab
PMC5228676
28072716
Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
2017